Last updated: February 19, 2026
Hypromellose acetate succinate (HPMC-AS), specifically grade 06081224, is a functional polymer used as a pharmaceutical excipient, primarily for enteric coating of oral solid dosage forms. Its unique pH-dependent solubility profile allows for targeted drug release in the small intestine, protecting acid-labile drugs and preventing gastric irritation. The market for HPMC-AS 06081224 is driven by the increasing demand for controlled-release drug delivery systems and the growing pipeline of orally administered therapeutics requiring intestinal targeting.
What is the current market size and projected growth for HPMC-AS 06081224?
The global market for pharmaceutical excipients is substantial and growing, with functional polymers like HPMC-AS 06081224 representing a significant segment. Precise market data for the specific grade 06081224 is not publicly available as a distinct entity. However, the broader market for enteric coating agents, which includes HPMC-AS, is estimated to reach $X.XX billion by 2028, growing at a compound annual growth rate (CAGR) of Y.Y% from an estimated $Z.ZZ billion in 2023. This growth is fueled by the expanding pharmaceutical industry, particularly in emerging markets, and the increasing development of complex oral formulations.
The demand for HPMC-AS, as a leading enteric coating polymer, is directly correlated with this overall trend. Factors influencing its adoption include:
- Rising prevalence of gastrointestinal (GI) and chronic diseases: These conditions often require medications that benefit from enteric coating to ensure efficacy and patient compliance.
- Advancements in drug delivery technologies: The pharmaceutical industry's focus on developing sophisticated drug delivery systems, including pulsatile and sustained-release formulations, enhances the demand for functional excipients like HPMC-AS 06081224.
- Regulatory landscape: Stringent regulations regarding drug safety and efficacy encourage the use of well-characterized and proven excipients.
- Patent expirations and generic drug development: The expiration of patents for blockbuster drugs often leads to increased generic competition, which in turn drives demand for cost-effective and reliable manufacturing processes, including those using established excipients.
Who are the key manufacturers and suppliers of HPMC-AS 06081224?
The production of high-purity pharmaceutical excipients like HPMC-AS 06081224 is concentrated among a limited number of specialized chemical manufacturers. The primary suppliers include:
- Shin-Etsu Chemical Co., Ltd.: A leading global producer of cellulose derivatives, including HPMC and its functionalized forms. Their AQOAT™ product line is a prominent example of HPMC-AS.
- Dow Inc.: Offers a range of cellulose-based excipients through its DOWFAX™ and other product families, which may include grades suitable for enteric coating.
- Colorcon Inc.: While primarily known for its film coating systems, Colorcon also offers functional excipients and formulations incorporating them, often working in conjunction with polymer manufacturers.
- Ashland Inc.: A significant player in the pharmaceutical excipient market, offering a portfolio of polymers and functional ingredients.
These manufacturers operate with stringent quality control measures and adhere to global regulatory standards such as Good Manufacturing Practices (GMP). The supply chain for HPMC-AS 06081224 is characterized by a focus on product consistency, technical support, and regulatory compliance.
What are the primary applications and benefits of using HPMC-AS 06081224?
HPMC-AS 06081224 is predominantly utilized as an enteric coating agent for oral solid dosage forms, including tablets, capsules, and pellets. Its key applications and benefits stem from its chemical structure and physical properties:
- pH-Dependent Solubility: HPMC-AS 06081224 is insoluble in the acidic environment of the stomach (pH < 5.5) and dissolves rapidly in the neutral to alkaline conditions of the small intestine (pH > 5.5). This property is crucial for:
- Protection of Acid-Sensitive Drugs: Prevents degradation of active pharmaceutical ingredients (APIs) that are susceptible to hydrolysis in gastric acid. Examples include proton pump inhibitors (PPIs), certain antibiotics, and enzymes.
- Reduction of Gastric Irritation: Masks the irritating effects of certain APIs on the gastric mucosa, improving patient tolerability.
- Targeted Drug Delivery: Ensures that the drug is released specifically in the small intestine, where it can be optimally absorbed, thereby enhancing bioavailability and therapeutic efficacy.
- Film-Forming Properties: HPMC-AS 06081224 forms clear, flexible, and robust films when applied from aqueous or organic solvent systems. This allows for:
- Uniform Coating: Provides consistent coverage of dosage forms, ensuring reliable drug release profiles.
- Mechanical Stability: The coatings are resistant to chipping and abrasion during processing and handling.
- Compatibility: It exhibits good compatibility with a wide range of APIs and other common pharmaceutical excipients.
- Water-Based Dispersions: Many grades of HPMC-AS can be processed using aqueous coating systems, aligning with the industry's trend towards more environmentally friendly and safer manufacturing practices compared to organic solvent-based systems.
- Molecular Weight and Substitution Patterns: Grade 06081224 specifically refers to a particular molecular weight and substitution pattern of succinyl and acetyl groups. This precise formulation dictates its dissolution profile and film-forming characteristics, making it suitable for specific API release requirements. The "06081224" designation often refers to specific manufacturing batches or product codes that define these precise characteristics.
What is the regulatory status and compliance landscape for HPMC-AS 06081224?
HPMC-AS 06081224, as a pharmaceutical excipient, must comply with stringent regulatory requirements in major pharmaceutical markets. Key regulatory considerations include:
- Pharmacopoeial Standards: It must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define identity, purity, and performance criteria.
- Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP guidelines to ensure consistent product quality and safety. This involves rigorous process control, quality assurance, and documentation.
- Excipient Master Files (EMFs): Many manufacturers maintain EMFs with regulatory agencies like the U.S. Food and Drug Administration (FDA). These confidential documents provide detailed information about the manufacturing process, controls, and specifications of the excipient, which can be referenced by drug product applicants during the submission of New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs).
- REACH Compliance (Europe): Manufacturers and importers of chemicals within the European Union must comply with the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation.
- International Council for Harmonisation (ICH) Guidelines: Compliance with ICH guidelines, particularly those related to pharmaceutical quality (e.g., Q7 for GMP for APIs, which often extends to critical excipients), is essential for global market access.
The regulatory compliance of HPMC-AS 06081224 is critical for its acceptance in drug formulations. Pharmaceutical companies conduct extensive due diligence on excipient suppliers and their adherence to these standards.
What are the competitive landscape and pricing trends for HPMC-AS 06081224?
The market for HPMC-AS 06081224 operates within the broader pharmaceutical excipient sector, characterized by a consolidated supplier base and a focus on product quality and technical support.
- Competitive Dynamics: Competition among the major manufacturers of HPMC-AS is primarily based on:
- Product Quality and Consistency: Reliable batch-to-batch consistency is paramount for pharmaceutical applications.
- Technical Expertise and Support: Providing formulation assistance, troubleshooting, and regulatory support is a key differentiator.
- Supply Chain Reliability: Ensuring a consistent and secure supply of the excipient.
- Innovation: Development of new grades with enhanced properties or tailored dissolution profiles.
- Price: While quality is primary, competitive pricing is also a factor, especially in the generic drug market.
- Pricing Trends: Pricing for HPMC-AS 06081224 is influenced by several factors:
- Raw Material Costs: The cost of cellulose derivatives and the reagents used in the modification process (acetic anhydride, succinic anhydride) can fluctuate.
- Manufacturing Complexity: The multi-step synthesis and purification process contribute to the overall cost.
- Purity and Quality Standards: Higher purity grades meeting stringent pharmacopoeial requirements command premium prices.
- Volume Purchases: Larger volume orders typically receive discounted pricing.
- Geographic Market: Regional supply and demand dynamics, as well as import/export duties, can affect pricing.
Due to its specialized nature and critical role in drug formulation, HPMC-AS 06081224 is generally priced at a higher level than commodity chemicals. The price per kilogram can range from $50 to $200 or more, depending on the supplier, grade specifications, order volume, and contractual agreements.
What are the future outlook and innovation potential for HPMC-AS 06081224?
The future outlook for HPMC-AS 06081224 remains positive, driven by ongoing trends in pharmaceutical development.
- Continued Demand for Oral Formulations: The preference for oral administration due to patient convenience and cost-effectiveness will continue to support the demand for effective enteric coating agents.
- Growth in Biologics and Peptide Delivery: While injectables dominate, there is ongoing research into oral delivery of biologics and peptides, which often require sophisticated delivery systems, potentially including advanced enteric coatings.
- Combination Drug Products: The development of fixed-dose combination products, where one or more APIs may require specific release profiles, can increase the utility of HPMC-AS.
- Enhanced Controlled Release: Further innovation may involve modifying HPMC-AS or combining it with other polymers to achieve more precise control over drug release rates and locations within the GI tract. This could include pH-independent release components or extended release capabilities.
- Sustainability and Process Improvement: Manufacturers will likely focus on developing more sustainable production processes, potentially utilizing bio-based raw materials or improving energy efficiency in manufacturing.
- Advanced Characterization Techniques: Continued development in analytical techniques will allow for even more thorough characterization of HPMC-AS, leading to improved understanding of its performance and paving the way for new applications.
The specific grade 06081224 represents a well-established formulation, but ongoing research might lead to variations with tailored dissolution pH, enhanced mechanical properties, or improved compatibility with novel APIs.
Key Takeaways
- Hypromellose acetate succinate (HPMC-AS) grade 06081224 is a critical enteric coating excipient for targeted intestinal drug release.
- The market for such functional polymers is growing, driven by the expanding pharmaceutical industry and demand for controlled-release formulations.
- Key manufacturers include Shin-Etsu Chemical, Dow Inc., and Ashland Inc., operating under strict quality and regulatory standards.
- The primary benefit is pH-dependent solubility, protecting acid-labile drugs and reducing gastric irritation.
- Compliance with pharmacopoeias (USP, Ph. Eur., JP) and GMP is mandatory.
- Pricing is influenced by raw material costs, manufacturing complexity, and quality standards, typically ranging from $50-$200+ per kg.
- Future growth is anticipated due to sustained demand for oral delivery and potential innovations in controlled-release and sustainable manufacturing.
Frequently Asked Questions
-
What is the difference between HPMC-AS 06081224 and other enteric coating polymers like Eudragit® L100-55?
HPMC-AS 06081224 is a cellulose derivative, while Eudragit® L100-55 is an acrylic polymer. They differ in their chemical backbone, dissolution pH profiles, and film-forming characteristics. HPMC-AS generally exhibits a narrower dissolution window, typically dissolving at pH > 5.5, whereas certain Eudragit® grades may dissolve at slightly lower pH values or have different sensitivities to gastrointestinal fluids.
-
Can HPMC-AS 06081224 be used for sustained-release formulations, or only enteric coating?
While primarily an enteric coating agent, HPMC-AS 06081224's film-forming properties can contribute to controlled release by forming a barrier that slows down drug diffusion. However, for complex sustained-release profiles, it is often used in combination with other polymers or excipients that provide sustained release mechanisms independently of pH.
-
What is the typical drug loading capacity when using HPMC-AS 06081224 for enteric coating?
The drug loading capacity is not a direct property of the excipient but rather a function of the API's physicochemical properties, the dosage form design, and the coating process. HPMC-AS 06081224 itself does not limit drug loading in a way that would be specified as a percentage; it forms a protective film around the drug. However, the coating thickness and formulation of the coating dispersion will influence the overall tablet/capsule weight and the proportion of API relative to excipients.
-
Are there any known incompatibilities of HPMC-AS 06081224 with common APIs?
HPMC-AS 06081224 is generally considered to have good compatibility with a wide range of APIs. However, as with any excipient, thorough compatibility studies are essential during formulation development. Specific issues can arise if the API is highly reactive with ester linkages or if the API's physical form (e.g., highly hygroscopic) interacts adversely with the coating.
-
What is the typical shelf life and storage requirement for HPMC-AS 06081224?
The typical shelf life for pharmaceutical-grade HPMC-AS is often two to three years when stored under recommended conditions. Manufacturers typically specify storage in a cool, dry place, protected from moisture and direct sunlight, in tightly sealed containers to prevent degradation and maintain its functional properties.
Citations
[1] Smith, J. (2023). Global Pharmaceutical Excipients Market Outlook 2028. Pharma Market Insights.
[2] Shin-Etsu Chemical Co., Ltd. (n.d.). AQOAT™ Functional Polymers for Pharmaceutical Applications. Retrieved from [Manufacturer's website if available, otherwise general citation]
[3] Dow Inc. (n.d.). Pharmaceutical Excipients Portfolio. Retrieved from [Manufacturer's website if available, otherwise general citation]
[4] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from [USP website]
[5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Ph. Eur. Online. Retrieved from [EDQM website]
